You are here: Industry Insights > china

News List

Launch of Anticancer Agent Halaven in China firstwordpharma
January 11, 2020
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has launched the in-house developed anticancer agent Halaven(R) (generic name: eribulin mesylate) in China.
Internally-developed vaccines reportedly approved in China europeanpharmaceuticalreview
January 09, 2020
According to a recent article, China has approved a number of home-grown vaccines, offering alternatives to global drugmakers’ products.
Timetable reportedly set for national vaccine tracking system in China europeanpharmaceuticalreview
December 18, 2019
A national vaccine tracking system in China will aim to be completed before 31 March 2020, a report has said.
Pharma and Biotech Review: Chinese Biopharmaceutical Industry: Key Developments and Growing Trends Neeta Ratanghayra
November 24, 2019
Between 2012 and 2016, China’s biopharma market grew from $9.4 billion to $22.8 billion, and the market is expected to touch $48.8 billion in sales by 2022.1
Thermo Fisher expands clinical trials capabilities in China biospectrumasia
September 26, 2019
To align with China's effort to encourage drug innovation, the newly expanded Suzhou facility will address the growing demand for drug development supply chain services and focus on high quality primary and secondary packaging solutions for customers and
Fresenius Medical Care launches new dialysis machine in China biospectrumasia
September 20, 2019
To stay alive, the patient will need to undergo long-term dialysis or receive a kidney transplant. Currently more than 600,000 patients in China had access to dialysis, but the estimated ESRD prevalence is much higher.
AstraZeneca amends collaboration with Ironwood for Linzess in China worldpharmanews
September 20, 2019
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong, S.A.R., China and China Macau, S.A.R., China for Linzess (linaclotide) ...
Signant Health brings its eConsent solution to China biospectrumasia
September 16, 2019
The investigator-initiated schizophrenia focus trial, which will be the first Chinese study using Signant's TrialConsent solution, will involve hundreds of patients from multiple sites.
China grants Tagrisso (osimertinib) marketing authorisation europeanpharmaceuticalreview
September 06, 2019
Following positive clinical trials, the Tagrisso drug has been given marketing authorisation in China for treatment of NSCLC.
Syntellix Asia, Chunli to introduce MAGNEZIX Medtech Devices in China biospectrumasia
September 04, 2019
Milestone contract signed between leading Chinese orthopaedic medtech supplier and Singapore based Asian subsidiary and hub of German world-market and technology leader in the area of bioabsorbable metallic implants for use in orthopaedic and trauma surge

Previous page 1 2 3 4 5 6 7 8 9 10 ... 38 39 Next page